321 related articles for article (PubMed ID: 19654315)
1. A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth in vivo.
Yagi N; Manabe I; Tottori T; Ishihara A; Ogata F; Kim JH; Nishimura S; Fujiu K; Oishi Y; Itaka K; Kato Y; Yamauchi M; Nagai R
Cancer Res; 2009 Aug; 69(16):6531-8. PubMed ID: 19654315
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells.
Amarzguioui M; Peng Q; Wiiger MT; Vasovic V; Babaie E; Holen T; Nesland JM; Prydz H
Clin Cancer Res; 2006 Jul; 12(13):4055-61. PubMed ID: 16818705
[TBL] [Abstract][Full Text] [Related]
3. Krüppel-like factor 5 promotes breast cell proliferation partially through upregulating the transcription of fibroblast growth factor binding protein 1.
Zheng HQ; Zhou Z; Huang J; Chaudhury L; Dong JT; Chen C
Oncogene; 2009 Oct; 28(42):3702-13. PubMed ID: 19668233
[TBL] [Abstract][Full Text] [Related]
4. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
[TBL] [Abstract][Full Text] [Related]
5. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system.
Pirollo KF; Rait A; Zhou Q; Hwang SH; Dagata JA; Zon G; Hogrefe RI; Palchik G; Chang EH
Cancer Res; 2007 Apr; 67(7):2938-43. PubMed ID: 17409398
[TBL] [Abstract][Full Text] [Related]
6. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
Yoshizawa T; Hattori Y; Hakoshima M; Koga K; Maitani Y
Eur J Pharm Biopharm; 2008 Nov; 70(3):718-25. PubMed ID: 18647651
[TBL] [Abstract][Full Text] [Related]
7. Calcium carbonate nanoparticle delivering vascular endothelial growth factor-C siRNA effectively inhibits lymphangiogenesis and growth of gastric cancer in vivo.
He XW; Liu T; Chen YX; Cheng DJ; Li XR; Xiao Y; Feng YL
Cancer Gene Ther; 2008 Mar; 15(3):193-202. PubMed ID: 18202713
[TBL] [Abstract][Full Text] [Related]
8. Tumor-homing glycol chitosan/polyethylenimine nanoparticles for the systemic delivery of siRNA in tumor-bearing mice.
Huh MS; Lee SY; Park S; Lee S; Chung H; Lee S; Choi Y; Oh YK; Park JH; Jeong SY; Choi K; Kim K; Kwon IC
J Control Release; 2010 Jun; 144(2):134-43. PubMed ID: 20184928
[TBL] [Abstract][Full Text] [Related]
9. Arthritic joint-targeting small interfering RNA-encapsulated liposome: implication for treatment strategy for rheumatoid arthritis.
Komano Y; Yagi N; Onoue I; Kaneko K; Miyasaka N; Nanki T
J Pharmacol Exp Ther; 2012 Jan; 340(1):109-13. PubMed ID: 21994423
[TBL] [Abstract][Full Text] [Related]
10. Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy.
Zheng C; Zheng M; Gong P; Deng J; Yi H; Zhang P; Zhang Y; Liu P; Ma Y; Cai L
Biomaterials; 2013 Apr; 34(13):3431-8. PubMed ID: 23375952
[TBL] [Abstract][Full Text] [Related]
11. Tailored design of Au nanoparticle-siRNA carriers utilizing reversible addition-fragmentation chain transfer polymers.
Kirkland-York S; Zhang Y; Smith AE; York AW; Huang F; McCormick CL
Biomacromolecules; 2010 Apr; 11(4):1052-9. PubMed ID: 20337403
[TBL] [Abstract][Full Text] [Related]
12. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles.
Carmona S; Jorgensen MR; Kolli S; Crowther C; Salazar FH; Marion PL; Fujino M; Natori Y; Thanou M; Arbuthnot P; Miller AD
Mol Pharm; 2009; 6(3):706-17. PubMed ID: 19159285
[TBL] [Abstract][Full Text] [Related]
13. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.
Yen MC; Lin CC; Chen YL; Huang SS; Yang HJ; Chang CP; Lei HY; Lai MD
Clin Cancer Res; 2009 Jan; 15(2):641-9. PubMed ID: 19147770
[TBL] [Abstract][Full Text] [Related]
14. A non-covalent peptide-based strategy for siRNA delivery.
Crombez L; Charnet A; Morris MC; Aldrian-Herrada G; Heitz F; Divita G
Biochem Soc Trans; 2007 Feb; 35(Pt 1):44-6. PubMed ID: 17233597
[TBL] [Abstract][Full Text] [Related]
15. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy.
Yang XZ; Dou S; Sun TM; Mao CQ; Wang HX; Wang J
J Control Release; 2011 Dec; 156(2):203-11. PubMed ID: 21839126
[TBL] [Abstract][Full Text] [Related]
16. PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells.
Liu XX; Rocchi P; Qu FQ; Zheng SQ; Liang ZC; Gleave M; Iovanna J; Peng L
ChemMedChem; 2009 Aug; 4(8):1302-10. PubMed ID: 19533723
[TBL] [Abstract][Full Text] [Related]
17. Liver target delivery of small interfering RNA to the HCV gene by lactosylated cationic liposome.
Watanabe T; Umehara T; Yasui F; Nakagawa S; Yano J; Ohgi T; Sonoke S; Satoh K; Inoue K; Yoshiba M; Kohara M
J Hepatol; 2007 Dec; 47(6):744-50. PubMed ID: 17822798
[TBL] [Abstract][Full Text] [Related]
18. Advances in the development of siRNA-based therapeutics for cancer.
Shen Y
IDrugs; 2008 Aug; 11(8):572-8. PubMed ID: 18683092
[TBL] [Abstract][Full Text] [Related]
19. Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA.
Liu B
Brief Funct Genomic Proteomic; 2007 Jun; 6(2):112-9. PubMed ID: 17670766
[TBL] [Abstract][Full Text] [Related]
20. Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy.
Kim WJ; Chang CW; Lee M; Kim SW
J Control Release; 2007 Apr; 118(3):357-63. PubMed ID: 17313987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
